Haw Par (Haw Par) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is Haw Par Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Haw Par is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Haw Par's Risk Assessment

For the Drug Manufacturers - General subindustry, Haw Par's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haw Par's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Haw Par's Risk Assessment falls into.

Haw Par (OTCPK:HAWPF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Haw Par Risk Assessment Related Terms

Thank you for viewing the detailed overview of Haw Par's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Haw Par (Haw Par) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (OTCPK:HAWPF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

H02:Singapore

Address

401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598

Website

https://www.hawpar.com

Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (Haw Par) Headlines

From GuruFocus

First Eagle Comments on Haw Par

By Holly LaFon Holly LaFon • 04-24-2018

Haw Par Stock Is Believed To Be Significantly Overvalued

By GF Value GF Value • 03-31-2021

Singapore Based Haw Par Selling at a Discount to NAV

By Holmes Osborne, CFA Holmes Osborne, CFA • 07-26-2016